Combination antifungal therapy for invasive mold infections involving polyenes: A case report and brief review of the literature

Infectious Diseases in Clinical Practice

Volumn 18, Issue 1, 2010, Pages 7-15

  Chaux, George E ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PREDNISONE; PYRROLE DERIVATIVE; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; COCCIDIOIDOMYCOSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LUNG TRANSPLANTATION; MOLD INFECTION; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PNEUMOCYSTIS JIROVECII INFECTION; PNEUMOCYSTOSIS; PREVALENCE; REVIEW; TREATMENT RESPONSE;

EID: 76149089580     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3181bf62e7     Document Type: Review

References (107)

1. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99-109.
2. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173-180.
3. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997;19:801-808.
4. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27:369-388.
5. Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new Bgold standard[. Clin Infect Dis. 2003;37:415-425.
6. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents. 2007;30:108-117.
7. Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007;29:1862-1886.
8. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med. 2008;29:198-210.
9. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
10. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
11. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
12. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Cin Microbiol Rev. 2007;20: 133-163.
13. Upton A, Marr KA. Emergence of opportunistic mold infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep. 2006;8:434-441.
14. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25:215-229.
15. Malani AN, Kauffman CA. Changing epidemiology of rare mold infections: implications for therapy. Drugs. 2007;67:1803-1812.
16. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
17. Nucci M, Marr KA, Queitoz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237-1242.
18. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concerns for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42:4419-4431.
19. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens current epidemiological trends. Clin Infect Dis. 2006:43;S3-S14.
20. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(suppl 1):48-66.
21. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections inpatients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068-1075.
22. Baddley JW, Pappas PG. Combination antifungal therapy for the treatment of invasive yeast and mold infections. Curr Infect Dis Rep. 2007;9:448-456.
23. Segal BH, Steinbach WJ. Combination antifungals: an update. Expert Rev Anti Infect Ther. 2007;5:883-892.
24. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
25. Hof H. Developments in the epidemiology of invasive fungal infectionsVimplications for the empiric and targeted antifungal therapy. Mycoses. 2008;51(suppl 1):1-6.
26. Groll AH, McNeil Grist L. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th international symposium on infections in the immunocompromised host: Thessaloniki, Greece, 22-25 June 2008. Int J Antimicrob Agents. 2009;33:101-104.
27. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989;8:323-330.
28. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23-32.
29. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7(suppl 2):8-24.
30. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Hematologica. 2006;91:986-989.
31. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis. 2005;41:521-526.
32. Procop GW, Roberts GD. Emerging fungal disease: the importance of the host. Clin Lab Med. 2004;24:691-719.
33. Kauffmann C. Zygomycosis: re-emergence of an old pathogen. Clin Infect Dis. 2004;39:588-590.
34. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-1360.
35. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-1277.
36. Goldman M, Pottage JC Jr, Weaver D. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine. 1993;72:143-150.
37. Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60-66.
38. Garcia-Effron G, Kontoyiannis DP, Lewis RE, et al. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181-4183.
39. Khan ZU, Mokaddas EM. Advances in therapy of invasive mycoses. Kuwait Med J. 2007;39:98-106.
40. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy. 2001;21:133s-148s.
41. Graybill JR. Lipid formulations for amphotericin B: does the emperor need new clothes? Ann Intern Med. 2006;124:921-923.
42. Herbrecht R, Natarajan-Ame S, Nivoix Y, et al. The lipid formulations of amphotericin B. Expert Opin Pharmacother. 2003;4:1277-1287.
43. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002;49(suppl 1):31-36.
44. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis. 2002;35:891-895.
45. Zaas AK. Echinocandins: a wealth of choiceVhow clinically different are they? Curr Opin Infect Dis. 2008;21:426-432.
46. Kitamura A, Someya K, Hata M, et al. Discovery of a small molecule inhibitor of A-1,6-glucan synthesis. Antimicrob Agents Chemother. 2009;53:670-677.
47. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503-509.
48. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-379.
49. von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341-347.
50. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604-1610.
51. Verweij P, Mennink-Kersten MASH. Issues with galactomannan testing. Med Mycol. 2006;44:S179-S183.
52. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253-259.
53. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006;173:707-717.
54. Mennink-Kersten MASH, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4:349-355.
55. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis. 2006; 43(suppl 1):S15.
56. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27-34.
57. Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis. 2001;33:1621-1627.
58. Pazos C, Ponton J, Del Palacio A. Contribution of (1-3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J ClinMicrobiol. 2005;43:299-305.
59. Senn L, Robinson JO, Schmidt S, et al. 1,3-b-D-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46:878-885.
60. White PL, Linton CJ, Perry MD, et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. 2006;42:479-486.
61. Badiee P, Kordbacheh P, Alborzi A, et al. Study on invasive fungal infections in immunocompromised patients to present a suitable early diagnostic procedure. Int J Infect Dis. 2009;13:97-102.
62. Tassi GF, Davies RJ, Noppen M. Advanced techniques in medical thoracoscopy. Eur Respir J. 2006;28:1051-1059.
63. Herth FJ, Ernst A. Innovative bronchoscopic diagnostic techniques: endobronchial ultrasound and electromagnetic navigation. Curr Opin Pulm Med. 2005;11:278-281.
64. Lass-Florl C, Resch G, Nachbaur E, et al. The value of computed tomographyYguided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007;45:e101-e104.
65. Flückiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly. 2006;136:447-463.
66. Maertens M, Theunissen K, Verhoef G, et al. Galactomannan and computed tomographyYbased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242-1250.
67. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527-1533.
68. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
69. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaxonaxole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347.
70. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
71. Ostrosky-Zeichner L. Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect. 2008;14(suppl 4):65-70.
72. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693-715.
73. Wasan KM, Sivak O, Rosland M, et al. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet\ and AmBisome\ in combination with caspofungin to rats infected with Aspergillus fumigatus. J Pharm Sci. 2007;96:1737-1747.
74. Te Dorsthorst DTA, Verweij PE, Meis JFG, et al. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itracoaxole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother. 2002;46:702-707.
75. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18:163-194.
76. Kamberi P, Atsuro H, Takayoshi T, et al. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice. Chemotherapy. 1998;44:55-62.
77. Sugar AM, Liu XP. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis. 1998;177:1660-1663.
78. Vazquez JA. Combination antifungal therapy: the new frontier. Future Microbiol. 2007;2:115-139.
79. Vazquez A. Combination antifungal therapy for mold infections: much ado about nothing. Clin Infect Dis. 2008;46:1889-1901.
80. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy. 2001;21:149SY64S.
81. Roy V, Ali LI, Carter TH, et al. Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease. J Infect. 2000;41: 273-275.
82. Verma A, Williams S, Trifilio S, et al. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease. Bone Marrow Transplant. 2004;33: 1065-1066.
83. Vazquez L, Mateos JJ, Sanz-Rodriquez C, et al. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica. 2005;90(suppl 12):ECR39.
84. Rickerts V, Atta J, Herrmann S, et al. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses. 2006;49(suppl 1):27-30.
85. Kaffarnik M, Utzolino S, Blaich A, et al. Successful multimodal therapy of invasive pulmonary and central nervous system aspergillosis in a neutropenic surgical patient: case report and literature review. Mycoses. 2008;51:74-78.
86. Ho DY, Lee JD, Rosso F, et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227-231.
87. Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A, et al. Disseminated fusariosis caused by Fusarium verticillioides in an acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2009;47:278-281.
88. Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist. 2007;12(suppl 2):2-6.
89. Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583-596.
90. Brandt ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother. 2003;15(suppl 2):36-47.
91. Revankar SG. Phaeohyphomycosis. Infect Dis Clin North Am. 2006;20:609-620.
92. Arunkumar MJ, Rajshekhar V, Chandy MJ, et al. Management and outcome of brain abscess in renal transplant recipients. Postgrad Med J. 2000;76:207-211.
93. Levin TP, Baty DE, Fekete T, et al. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J Clin Microbiol. 2004;42:4374-4378.
94. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev of Infect Dis. 1990;12:1147-1201.
95. Popp AI, White MH, Quadri T, et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis. 1999;3:157-160.
96. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025-1032.
97. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292-299.
98. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
99. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2005;40(suppl 6):S392-S400.
100. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 920 reported cases. Clin Infect Dis. 2005;41:634-653.
101. Sims CR, Ostrosky-Zeichner L. Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res. 2007;38:90-93.
102. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364-371.
103. Meletiadis J, Petraitis V, Petraitiene R. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194:1008-1018.
104. Rieger CT, Ostermann H, Kolb HJ, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol. 2008;87:915-922.
105. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337-349.
106. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107:2888-2897.
107. Steinbach WJ. Combination antifungal therapy for invasive aspergillosisVis it indicated? Med Mycol. 2006;44(suppl):373-382.